THRD insider transaction filings
Third Harmonic Bio, Inc. — 42 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2025-08-14. Screen THRD transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for THRD between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — Third Harmonic Bio, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-08-14 | 4 | Murphy Christopher M. — Chief Financial & Bus. Officer | Other (J): 47,500 (derivative) @ $0 | EDGAR |
| 2025-08-14 | 4 | Seidel Hans Martin — Director | Other (J): 85,753 · Other (J): 53,090 (derivative) @ $0 | EDGAR |
| 2025-08-14 | 4 | Gladstone Michael — Director, 10% owner | Other (J): 43,584 (derivative) @ $0 | EDGAR |
| 2025-08-14 | 4 | Holles Natalie C. — CEO, Director | Other (J): 1,218,836 · Other (J): 998,854 (derivative) @ $0 · Other (J): 50,000 (derivative) @ $0 | EDGAR |
| 2025-08-14 | 4 | Bonita David P — Director | Other (J): 5,779,071 · Other (J): 43,584 (derivative) @ $0 | EDGAR |
| 2025-08-14 | 4 | Soloway Thomas P — Director | Other (J): 120,166 (derivative) @ $0 | EDGAR |
| 2025-08-14 | 4 | Iwicki Mark T — Director | Other (J): 128,631 · Other (J): 83,296 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | Murphy Christopher M. — Chief Financial & Bus. Officer | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-01-17 | 4 | Murphy Christopher M. — Chief Financial & Bus. Officer | Grant/award (A): 140,000 (derivative) @ $0 · Grant/award (A): 17,500 (derivative) @ $0 | EDGAR |
| 2025-01-17 | 4 | Dittman Jennifer — Chief Operating Officer | Grant/award (A): 92,000 (derivative) @ $0 · Grant/award (A): 11,500 (derivative) @ $0 | EDGAR |
| 2025-01-17 | 4 | Person Julie — CHIEF ADMINISTRATIVE OFFICER | Grant/award (A): 100,000 (derivative) @ $0 · Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2025-01-17 | 4 | Dean Dennis — Chief Nonclinical Dev. Officer | Grant/award (A): 92,000 (derivative) @ $0 · Grant/award (A): 11,500 (derivative) @ $0 | EDGAR |
| 2025-01-17 | 4 | Dinsmore Christopher — Chief Scientific Officer | Grant/award (A): 116,000 (derivative) @ $0 · Grant/award (A): 14,500 (derivative) @ $0 | EDGAR |
| 2025-01-17 | 4 | Conner Edward R. — Chief Medical Officer | Grant/award (A): 132,000 (derivative) @ $0 · Grant/award (A): 16,500 (derivative) @ $0 | EDGAR |
| 2025-01-17 | 4 | Holles Natalie C. — CEO, Director | Grant/award (A): 400,000 (derivative) @ $0 · Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-11-12 | 4 | Conner Edward R. — Chief Medical Officer | Option exercise (M): 2,117 @ $4.20 · Sale (S): 2,117 @ $15 · Option exercise (M): 2,117 (derivative) @ $0 | EDGAR |
| 2024-11-05 | 4 | Atlas Venture Fund XI, L.P. — 10% owner | Other (J): 515,688 @ $0 | EDGAR |
| 2024-10-31 | 4 | BVF PARTNERS L P/IL BIOTECHNOLOGY VALUE FUND L P BVF I GP LLC BIOTECHNOLOGY VALUE FUND II LP BVF II GP LLC Biotechnology Value Trading Fund OS LP BVF Partners OS Ltd. BVF GP HOLDINGS LLC BVF INC/IL LAMPERT MARK N | Sale (S): 538,420 @ $14.30 · Sale (S): 396,963 @ $14.30 · Sale (S): 64,617 @ $14.30 | EDGAR |
| 2024-10-30 | 4 | Conner Edward R. — Chief Medical Officer | Option exercise (M): 2,673 @ $4.20 · Sale (S): 2,673 @ $15 · Option exercise (M): 2,673 (derivative) @ $0 | EDGAR |
| 2024-09-20 | 4 | Person Julie — CHIEF ADMINISTRATIVE OFFICER | Option exercise (M): 503 @ $4.20 · Sale (S): 503 @ $14 · Option exercise (M): 9,497 @ $4.20 · Sale (S): 9,497 @ $14.29 · Option exercise (M): 503 (derivative) @ $0 · Option exercise (M): 9,497 (derivative) @ $0 | EDGAR |
| 2024-09-20 | 4 | Conner Edward R. — Chief Medical Officer | Option exercise (M): 4,790 @ $4.20 · Sale (S): 4,790 @ $15 · Option exercise (M): 4,790 (derivative) @ $0 | EDGAR |
| 2024-06-28 | 4 | Person Julie — CHIEF ADMINISTRATIVE OFFICER | Option exercise (M): 10,000 @ $4.20 · Sale (S): 10,000 @ $12.46 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2024-06-28 | 4/A | Dinsmore Christopher — Chief Scientific Officer | Grant/award (A): 297,000 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Dittman Jennifer — Chief Development Oper Officer | Grant/award (A): 494 @ $4.20 · Sale (S): 494 @ $14.17 · Option exercise (M): 494 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Seidel Hans Martin — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Gladstone Michael — Director, 10% owner | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Bonita David P — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Soloway Thomas P — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Iwicki Mark T — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2024-05-22 | 4 | Dittman Jennifer — Chief Development Oper Officer | Grant/award (A): 1,042 @ $4.30 · Sale (S): 1,042 @ $14 · Option exercise (M): 1,042 (derivative) @ $0 | EDGAR |
| 2024-05-20 | 4 | Dittman Jennifer — Chief Development Oper Officer | Grant/award (A): 16,666 @ $4.30 · Grant/award (A): 6,912 @ $4.20 · Sale (S): 23,578 @ $14.04 · Grant/award (A): 100,000 (derivative) @ $0 · Option exercise (M): 16,666 (derivative) @ $0 · Option exercise (M): 6,912 (derivative) @ $0 | EDGAR |
| 2024-05-20 | 4 | Dean Dennis — Chief Nonclinical Dev. Officer | Grant/award (A): 210,000 (derivative) @ $0 | EDGAR |
| 2024-05-20 | 4 | Dinsmore Christopher — Chief Scientific Officer | Grant/award (A): 210,000 (derivative) @ $0 | EDGAR |
| 2024-05-10 | 4 | Holles Natalie C. — CEO, Director | Option exercise (M): 20,222 @ $4.20 · Sale (S): 20,222 @ $12.18 · Option exercise (M): 20,222 (derivative) @ $0 | EDGAR |
| 2024-04-15 | 4 | Holles Natalie C. — CEO, Director | Option exercise (M): 13,558 @ $4.20 · Sale (S): 13,558 @ $12.19 · Option exercise (M): 13,558 (derivative) @ $0 | EDGAR |
| 2024-04-08 | 4 | Person Julie — CHIEF ADMINISTRATIVE OFFICER | Option exercise (M): 1,107 @ $4.20 · Sale (S): 1,107 @ $10 · Option exercise (M): 1,107 (derivative) @ $0 | EDGAR |
| 2024-03-28 | 4 | MCDONOUGH GEOFF — Director | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2024-01-09 | 4 | Person Julie — Chief Administrative Officer | Grant/award (A): 116,000 (derivative) @ $0 | EDGAR |
| 2024-01-09 | 4 | Murphy Christopher M. — Chief Financial & Bus. Officer | Grant/award (A): 410,000 (derivative) @ $0 | EDGAR |
| 2024-01-09 | 4 | Conner Edward R. — Chief Medical Officer | Grant/award (A): 133,000 (derivative) @ $0 | EDGAR |
| 2024-01-09 | 4 | Holles Natalie C. — CEO, Director | Grant/award (A): 396,000 (derivative) @ $0 | EDGAR |
| 2024-01-05 | 4 | Holles Natalie C. — CEO, Director | Grant/award (A): 396,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Third Harmonic Bio, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2025-07-31 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-07-21 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2025-06-12 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-11 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2025-04-22 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2025-04-14 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-03-27 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-03-11 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-02-11 | 8-K | 2.02 — Results of Operations and Financial Condition ? 7.01 — Regulation FD Disclosure | EDGAR |
| 2024-11-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=THRD returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →